SEC Form PREM14C filed by Channel Therapeutics Corporation
$CHRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)
FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not rep
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ:LGND) and Channel Therapeutics Corporation ("Channel") (NYSE:CHRO), a pioneer i
4 - Channel Therapeutics Corp (0001919246) (Issuer)
4 - Channel Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
DEFM14C - Channel Therapeutics Corp (0001919246) (Filer)
10-Q - Channel Therapeutics Corp (0001919246) (Filer)
PREM14C - Channel Therapeutics Corp (0001919246) (Filer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)
4 - Chromocell Therapeutics Corp (0001919246) (Issuer)